Psoriasis Trial, Recruiting (NCT07039110)

Psoriasis Trial, Recruiting NCT07039110 Sponsor: AbbVie Condition: Psoriasis

Printed from Voxsanity (voxsanity.com.au) — NCT07039110 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Psoriasis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been confirmed by their treating doctor to have moderate-to-severe plaque psoriasis, with or without joint involvement, before enrolling in the study.
People for whom treatment with risankizumab is appropriate according to the official prescribing guidelines and product information for their region.
People whose doctor has already decided to prescribe risankizumab separately from, and before, any decision about joining this study.

Who may not be able to join:

People who have been diagnosed with a sleep disorder that they are currently receiving treatment for.
People who are currently taking part in, or have taken part in, another clinical trial or observational study within the last 30 days.
People who are currently receiving certain other specialised medications for any condition — including biologic treatments, JAK inhibitors, TYK2 inhibitors, or PDE4 inhibitors (confirm with trial site if unsure whether a current medication falls into these categories).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: ABBVIE INC., AbbVie

Phone: 844-663-3742

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07039110

Sponsor: AbbVie

Phase: Not Applicable

Status: Recruiting

Condition: Psoriasis

Trial contact: 844-663-3742

More information: https://clinicaltrials.gov/study/NCT07039110

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been confirmed by their treating doctor to have moderate-to-severe plaque psoriasis, with or without joint involvement, before enrolling in the study.
People for whom treatment with risankizumab is appropriate according to the official prescribing guidelines and product information for their region.
People whose doctor has already decided to prescribe risankizumab separately from, and before, any decision about joining this study.

Who may not be able to join:

People who have been diagnosed with a sleep disorder that they are currently receiving treatment for.
People who are currently taking part in, or have taken part in, another clinical trial or observational study within the last 30 days.
People who are currently receiving certain other specialised medications for any condition — including biologic treatments, JAK inhibitors, TYK2 inhibitors, or PDE4 inhibitors (confirm with trial site if unsure whether a current medication falls into these categories).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

AbbVie

Registry

ClinicalTrials.gov

Start date

9 September 2025

Est. completion

1 March 2028

Where this trial is recruiting

🇨🇦 Canada 🇨🇿 Czechia 🇫🇷 France 🇩🇪 Germany 🇬🇷 Greece 🇮🇹 Italy 🇯🇵 Japan 🇪🇸 Spain

Primary endpoints

Proportion of participants achieving a Dermatology Life Quality Index (DLQI) score of 0 or 1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov